Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2868 in Advanced Malignant Tumors
NCT05198505Phase 1Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Jun 2023
- Modality
- Immunotoxins, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2868 in advanced malignant solid tumor, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 10 months, Recommended Phase II Dose at 10 months and 2 more. Status: unknown.
02
Drugs
TQB2868
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05198505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198505.